Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the 2019 Annual Meeting of the American Epilepsy Society (AES) December 6-10, 2019 in Baltimore, MD. Meeting attendees are encouraged to visit booth #526 ... Read More
Program Provides Access and Affordability for Patients Seeking Treatment for Acute Migraine
Maple Grove, MN – November 18, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has added Zembrace® SymTouch® (sumatriptan) Injection 3 mg ... Read More
Left to Right: NCPA President Bill Osborn,PharmD; Steve Moore, PharmD (winner); and Mike McBride of Upsher Smith
NCPA AWARD SPONSORED BY UPSHER-SMITH FOR ELEVENTH CONSECUTIVE YEAR
Maple Grove, MN – October 29, 2019 – Upsher-Smith Laboratories, LLC ... Read More
VISIT BOOTH #414 TO LEARN ABOUT VIGADRONE® (VIGABATRIN) FOR ORAL SOLUTION AND ITS SAVINGS AND SUPPORT PROGRAM
Maple Grove, MN – October 22, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending ... Read More
DELIVERS THE EFFICACY OF AN INJECTABLE WITH THE CONVENIENCE OF A NASAL SPRAY
Maple Grove, MN – October 2, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith)today announced the launch of Tosymra™ (sumatriptan) Nasal Spray, 10 mg for ... Read More
Maple Grove, MN – September 20, 2019 – UpsherSmith Laboratories, LLC (Upsher-Smith) today announced that executives from its parent company, Sawai Pharmaceutical Co., Ltd. (Sawai) including Sawai’s President, Mitsuo Sawai and General Manager of External ... Read More
Osaka, Japan – August 28, 2019 – Sawai Pharmaceutical Co., Ltd. (Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of its partial change application by the Ministry of Health, Labour and Welfare (MHLW) ... Read More
Maple Grove, MN – August 27, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Morphine Sulfate Tablets, CII, 15 and 30 mg. The morphine sulfate tablet market had U.S. sales of approximately ... Read More
